You can’t fix the global antibiotic pipeline with hope and prayer, or whatever it is pharma’s been using to stall the collapse. Enter Kinvard Bio, out of Raleigh, North Carolina. And before you ask: yes, it’s a Harvard spin-out. But this one’s got actual horsepower under the hood, not just a crimson bumper sticker.
Kinvard Bio just secured a $2.7 million non-dilutive follow-on grant from CARB-X, that’s Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator for the uninitiated. It’s not easy money. It’s milestone-triggered, rigor-tested capital for companies tackling the Everest of drug discovery: antimicrobial resistance. With this round, Kinvard Bio’s confirmed funding rises to $3.9 million, plus an undisclosed seed round that came in February 2025, backed by Kineticos AMR Accelerator Fund I (KAMRA I).
The founding trio, Dr. Lloyd J. Payne, D.Phil. (CEO), Dr. Kelvin Wu, Ph.D. (VP, Research), and Dr. Ben Tresco, Ph.D. (VP, Chemistry), aren’t chasing headlines. They’re going after respiratory killers, complicated UTIs, and nontuberculous mycobacterial lung disease. What makes this more than another noble AMR play is the chemistry: oxepanoprolinamides, a next-gen class of synthetic, ribosome-hijacking antibiotics that walk into the room unbothered by traditional resistance.
This isn’t your typical antibiotic program with a fancy prefix and a repackaged scaffold. The OPPs are fully synthetic, orally bioavailable, and built to dance around multigene resistance mechanisms like it’s choreographed. They’re gunning for both IV and oral routes, with real IV-to-oral step-down flexibility that hospitals can actually use. The platform is rooted in a decade of hardcore chemistry from Prof. Andrew G. Myers’ lab at Harvard, now running with exclusive rights and a roadmap that stretches through IND and into Phase 1 by 2028.
What’s most impressive isn’t just the science, it’s the infrastructure. A lean, virtual model with a Raleigh-based chemistry hub, partnerships with Harvard, and a team that’s tight but growing fast. With Obadiah Plante, Ph.D. stepping in as SVP of Research and Nathan Finger leading Ops and Finance, the company’s now fully rigged for preclinical takeoff.
Steven Gelone, Pharm.D., chairs the board like a guy who’s scaled this mountain before, because he has. And with Shailesh Maingi and the Kineticos crew backing the mission, you’re looking at a team that knows how to build in high-stakes biology without the usual biotech delusion.
Antimicrobial resistance isn’t a buzzword. It’s a death sentence waiting for better answers. Kinvard Bio just might be one of them.
Startups Startup Funding Early Stage Venture Capital Biotech Biotechnology Bioscience Healthcare HealthTech DeepTech Infrastructure Technology Innovation Tech Ecosystem Startup Ecosystem Hiring Tech Hiring
If software engineering peace of mind is what you crave, Vention is your zen.
